Company
Travere
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
1
1 still marketed
Novel approvals
1
Approvals since 2021
4
Originals and new uses
Phase 3 trials
5
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
- Pegtibatinase as a Treatment for Participants With Classical Homocystinuria (HCU) Receiving Standard of Care TreatmentPivotal-lookingRecruiting
Travere Therapeutics, Inc.Industry
NCT06247085 · 70 participants (planned) · Start Dec 28, 2023 · Primary completion Aug 2027
Drug: Pegtibatinase · For: Homocystinuria
Sites: Phoenix, Arizona; New Haven, Connecticut; Atlanta, Georgia · 52 sites in all
Marketed drugs (1)
Newest FDA action first.
- Filspari Sparsentan · 2023
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.